title: Radiofrequency ablation of lung malignancies: where do we stand?
abstract: Percutaneous radiofrequency (RF) ablation is a minimally invasive technique used to treat solid tumors. Because of its ability to produce large volumes of coagulation necrosis in a controlled fashion, this technique has gained acceptance as a viable therapeutic option for unresectable liver malignancies. Recently, investigation has been focused on the clinical application of RF ablation in the treatment of lung malignancies. In theory, lung tumors are well suited to RF ablation because the surrounding air in adjacent normal parenchyma provides an insulating effect, thus facilitating energy concentration within the tumor tissue. Experimental studies in rabbits have confirmed that lung RF ablation can be safely and effectively performed via a percutaneous, transthoracic approach, and have prompted the start of clinical investigation. Pilot clinical studies have shown that RF ablation enables successful treatment of relatively small lung malignancies with a high rate of complete response and acceptable morbidity, and have suggested that the technique could represent a viable alternate or complementary treatment method for patients with non-small cell lung cancer or lung metastases of favorable histotypes who are not candidates for surgical resection. This article gives an overview of lung RF ablation, discussing experimental animal findings, rationale for clinical application, technique and methodology, clinical results, and complications.
authors.affiliation: Division of Diagnostic and Interventional Radiology, Department of Oncology, Transplants, and Advanced Technologies in Medicine, University of Pisa, Via Roma 67, I-56126, Pisa, Italy. Lencioni@do.med.unipi.it
authors.forename: Riccardo
authors.initials: R
authors.lastname: Lencioni
authors.forename: Laura
authors.initials: L
authors.lastname: Crocetti
authors.forename: Roberto
authors.initials: R
authors.lastname: Cioni
authors.forename: Alfredo
authors.initials: A
authors.lastname: Mussi
authors.forename: Gabriella
authors.initials: G
authors.lastname: Fontanini
authors.forename: Marcello
authors.initials: M
authors.lastname: Ambrogi
authors.forename: Chiara
authors.initials: C
authors.lastname: Franchini
authors.forename: Dania
authors.initials: D
authors.lastname: Cioni
authors.forename: Olivia
authors.initials: O
authors.lastname: Fanucchi
authors.forename: Raffaello
authors.initials: R
authors.lastname: Gemignani
authors.forename: Rubia
authors.initials: R
authors.lastname: Baldassarri
authors.forename: Carlo Alberto
authors.initials: CA
authors.lastname: Angeletti
authors.forename: Carlo
authors.initials: C
authors.lastname: Bartolozzi
mesh_terms: D000818:Animals; D017115:Catheter Ablation / Q000009:adverse effects / Q000379:methods*; D004195:Disease Models, Animal; D005471:Fluoroscopy / Q000379:methods; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging / Q000601:surgery; D008175:Lung Neoplasms / Q000601:surgery*; D011817:Rabbits; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome